Joanna K. Chorazeczewski, MHS

PhD student @uchicagoimmuno. Prev employement: @FDACBER & @PennGTP. Prev schools: @JohnsHopkinsSPH & @LoyolaChicago

[Joanna K. Chorazeczewski, MHS @jchorazeczewski]

@UCCancerCenter @UChicagoCCB @UChicagoCOI @KlineLabUChi

[Moderna @moderna_tx]

This morning, we announced a new collaboration with the nonprofit Institute for Life Changing Medicines (ILCM) to develop a new #mRNA therapeutic (mRNA-3351) for Crigler-Najjar Syndrome Type 1 (CN-1), an ultra-rare disease. Read more: https://t.co/Zp4ZxTVssv